Ente Ecclesiastico Ospedale Generale Regionale Miulli — Clinical Trial Site

18 Registered trials

9 Currently recruiting

Organisation

Ente Ecclesiastico Ospedale Generale Regionale Miulli

Location

Acquaviva Delle Fonti, Italy

Identifier

ORG-100047744

Address

Strada Provinciale No 127, Acquaviva Santeramo Km 4 100, 70021, Italy

Departments

Cardiologia
Cardiologia e U.T.I.C.
Cardiology
Division of Endocrinology and Metabolic Diseases
Hepatobiliary and Pancreatic Unit
Medicina Interna
Medicine - Division of Nephrology
N/A
Oncology
U.O.C. ENDOCRINOLOGIA
U.O.C. Nefrologia e Dialisi
UOC di Cardiologia e UTIC
UOSD Oncologia Ginecologica
Urologia
Urology

Clinical trials at this site (18)

Search interface

A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit… Pending

2024-515555-38-01 NON SMALL CELL LUNG CANCER 4
A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending

2025-522475-28-00 Pulmonary Hypertension (PH) with Heart Failure with pre 5
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
COLCOT-T2D Recruiting

2024-516646-19-00 Type 2 diabetic patients with no prior cardiovascular ( 5 2025-08-15
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Hereditary Angioedema 5 2025-03-28
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an… Recruiting

2024-512900-20-00 Non-muscle invasive bladder cancer (NMIBC) 7 2025-01-30
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Recurrent ovarian cancer 5 2025-01-09
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 BRCA wild-type advanced ovarian, fallopian tube and pri 4 2024-12-09
Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanc… Recruiting

2024-518656-23-00 locally advanced cholangiocarcinoma 4 2023-09-01
CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult… Ended

2024-516247-62-00 Hereditary Angioedema 5 2025-03-10
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended

2023-506153-38-00 High-risk localized or locally advanced prostate cancer 5 2019-07-11
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24